



May 2022

Executive Summary

Value Proposition: Cytimmune uses immune system molecules called cytokines and proprietary nanoparticles to create safer, more effective combination therapies to treat solid tumor cancers. Our platform can deliver combinations of drugs that would otherwise not be possible due to toxicity or poor biodistribution. Platform delivery can nearly eliminate toxicities and result in 10-100x increases of therapy inside the tumor.

Leadership Team: CEO, Saba Malak, holds an engineering degree from U-Penn, and an MBA from Harvard. He previously was a Principal at BCG and an MD at Putnam. Founder, Giulio Paciotti, has 20+ years of experience in nanomedicine development. Leadership and the Board of Directors have more than 100+ years in biotech/pharma industry experience.

Challenge: Solid tumor cancers are resistant to treatment with traditional chemo and modern immunotherapies because 1) it's hard to get therapy into tumors and 2) tumors are immunosuppressive. Combination therapies that attack solid tumors along multiple axes are the best approach, but cancer drug toxicities and poor delivery systems make these therapies nearly impossible.

Solution: A class of drugs called cytokines can break open the tumor, drive an immune response, and induce cancer cells to kill themselves, but they are too toxic. Nanoparticles can safely deliver combination therapies, but they fail to penetrate deep into the tumor. Cytimmune uses cytokines on nanoparticles to open the tumor and enable delivery of novel combination therapies.

Technology: Cytimmune nanoparticles are designed to target any solid tumor and avoid healthy tissues. The particles carry a cytokine that rapidly breaks open the tumor, allowing our nanoparticles and other therapies to penetrate, permeate, and concentrate inside. This can improve standard of care and enable novel therapies. Our nanoparticles can carry multiple large and small molecules.

Market: Cytimmune's cytokine therapies and enhanced chemotherapies have pan-solid tumor applicability. In the US alone, 518,000 people are projected to die from solid tumor cancers and approximately 1M individuals will be diagnosed with advanced disease. Our therapies are systemically delivered and target both primary and secondary tumors.

Revenue Model: We have developed multiple proof of concept nanomedicines, each of which has blockbuster potential. We will advance clinical programs to demonstrate the power of our approach for use with immuno-oncology, chemotherapy, and precision cancer medicines. We anticipate significant out-licensing, co-development of assets, and ultimately acquisition by a larger pharma company.

Financial Projections

The current round of \$10M will enable Cytimmune to initiate a phase 2 clinical trial for our lead asset, bring a second asset into a phase 1 clinical trial, and complete preparation for large pharma partner engagement.

Year	1	2	3	4	5
Investment	10M	60M		120M	
Outcome	Complete Manufacturing Begin Partnering Discussions	First CO-Development with Pharma Partner	Out-license First Asset	IPO, Private Raise, or Sale	Sale to Big Pharma
Clinical Development		Begin Phase 2 Clinical Studies Open IND on 2 nd Asset	Phase 2 Early Readout Begin Phase 1	Phase 2 Complete Phase 1 Complete	

WEBSITE: www.cytimmue.com

Headquarters:

15010 Broschart Road, Suite 180
Rockville MD, 20850

Industry: Biotechnology

Founder, CSO:

Guilio Paciotti

Leadership:

Saba Malak, CEO
David Oarr, President

Partners, Grant Providers:

NCI, NCL, NIST

Seeking Financing of: \$10M

Previous Funding; 25M+

Use of Funds:

Manufacturing/research for clinical trials, regulatory engagement, partnering activities

Contact: doarr@cytimmune.com